Dr. Wang’s participation in the PRIOH-1 clinical trial is wrapping up, and the sponsor has shared that the study drug
has demonstrated clinically meaningful and statistically significant superiority in lesion healing up to 28-day
of treatment compared with the investigator’s choice. Importantly, Pritelivir showed a favorable
safety profile and was well tolerated.
Links to press releases if anyone’s interested:
Congratulations, Dr. Wang!